Seeking Alpha

Jeremy's friend

Jeremy's friend
Send Message
View as an RSS Feed
View Jeremy's friend's Comments BY TICKER:
Latest  |  Highest rated
  • Amarin: Is No News Good News? [View article]
    FDA is playing the same game that they played with NCE.
    Jan 20 04:49 PM | Likes Like |Link to Comment
  • Amarin: How Cost Cutting Affects Cash Burn And Profitability [View article]
    Matt Herper wrote to me in reply--Amarin's value is only there with Reduce-It study. It would plunge if Reduce-It study was stopped.
    Amarin has to find a way to continue with Reduce-It study for 2 more years. Hopefully by Dec.2015--they should get results better than Jelis.
    Nov 15 01:06 PM | 2 Likes Like |Link to Comment
  • Amarin Investor Discontent Turns To Mutiny [View article]
    Dr.Yokoyama has written that Inflammation reduction was key in CV events reduction.(2007-2008).
    This was backed up with an article in Journal Of Atheroscl. in 2011 sent to me by Dr.Barry Sears.This article used AA/EPA ratio or EPA/AA ratio in Japanese preference. AA/EPA dropped from 1.6 to 0.8
    Now Dr.Sears explained to me that the real benefits of EPA comes from lower inflammation--a leading indicator of C-RP--He even said--in 2011 that Amarin should be focussing on Inflammation reduction--he prefered using EPA of 6 gram/day for results similar to Crestor-(pretty fast in 2 yrs.)
    Could you please explain to me that -Why Amarin did not talk about C-RP reduction? Rather than harp on Trigylceride-why not talk of true benefit of EPA--as this ratio AA/EPA reduction leads to lower CV events.?
    Next question: Is it too late to redefine Vascepa study focussing on Inflammation?
    Nov 2 06:29 PM | 1 Like Like |Link to Comment
  • Amarin Investor Discontent Turns To Mutiny [View article]
    Steve Rosenman,
    Please read my comment on Vascepa in reply to your post here. Let me know-whether a study focusing on C-RP reduction is possible now.Dr.Yokoyama has said often that it EPA/AA ratio that reduced inflammation and produced CV reduction.
    Nov 2 08:29 AM | Likes Like |Link to Comment
  • Amarin Investor Discontent Turns To Mutiny [View article]
    You seem to know more.My question: Jelis-Key investigator said that Inflammation and thrombosis played a major role in Reduction in CV events. Later 2 articles came out in 2011 and 2013-where they analyzed the data to confirm whether Inflammation reduction was statiscally significant.Dr.Barry Sears sent me 2011 article and he told me that Amarin is on wrong path touting Trigylceride reduction and not inflammation reduction.Barry uses AA/EPA ratio and Japanese use EPA/AA ratio in their analysis.Barry told me that 6 gram of EPA would have produced faster results for Reduce-It study.He believes Americans AA/EPA ratio is over 3.0--danger point.
    Now my question: Anchor study showed significant reduction in C-RP. Is there a possibility that FDA application could be changed to reflect C-RP reduction?
    In 1999,Epadel used in Jelis study was done with old statins.Now Crestor was approved for high C-RP.Its study yielded great results in 2 years.
    Will FDA say--"We already have Crestor for C-RP reduction"?Vascepa could be used by patients who can not tolerate Crestor.So a different subgroup would have to be enrolled. C-RP reduction results were big and sooner.Vascepa results could prove that it reduces C-RP in larger study.
    Your expert opinion please.
    Nov 2 08:24 AM | Likes Like |Link to Comment
  • Did The FDA Just Issue Amarin's Death Blow Again? [View article]
    Rosenman;
    Dr.Yokoyama of JELIS study said," Benefit of Epadel-96% pure EPA came from reduction in inflammation that reduced CV events significantly".He said," It was not thru trigylcerides."
    Recent article in 2011 and 2013 further provided evidence when they used AA/EPA ratio--rather EPA/AA ratio to bolster that it is the benefit of inflammation reduction.
    Question to all the experts(author and Rosenman):
    Can Amarin broaden the reasons to include C-RP reduction?
    Oct 30 01:41 PM | 3 Likes Like |Link to Comment
  • Amarin: Potentially Worth $3 To $4 Without Expanded Approval [View article]
    In the past,we have not listened to Matt Herper of Forbes or Dr.Nissen and other cardiologists.
    They are saying: Continue REDUCE-IT study.
    Oct 27 01:13 PM | Likes Like |Link to Comment
  • Amarin: Potentially Worth $3 To $4 Without Expanded Approval [View article]
    Finding a partner in current situation is almost impossible as their terms will be awful Remember the loan terms--15% interest rate-patents as collateral.
    The only option is:
    1) Must continue Reduce-It study thru the end of 2015.Costs could be 55 mil.$ total
    2) So ask all officers to accept 75% pay cut and if they don't like-then can leave.Many of them made millions in 2011,2012 and 2013. Ask Joe Z. to accept ZERO or $1 salary.
    3) Run a very tight ship--no more going to conferences.Keep all other costs down.Cut R&D as much as possible.
    These actions are possible if the board of directors get PROACTIVE now.
    Oct 27 01:11 PM | 1 Like Like |Link to Comment
  • Amarin Could Still Turn Profitable [View article]
    REDUCE-IT study should be continued at all cost.
    That's the opinion of Matt Herper of Forbes and Dr.Nissen of the Cleveland Clinic.
    By end of 2015,we should know if Vascepa is likely to be successful .
    Without this study--doctors will be turned off from Vascepa.
    So how do we conduct this study and slow rate of cash use?
    CUT BACK top salaries by 75% or more.These top officers made millions in 2011,2012 and 2013. I think board of directors should demand this. If Joe Z. is truly believer of Vascepa-he should agree to 1$/yr. salary for 2 years.
    Oct 27 12:12 PM | Likes Like |Link to Comment
  • Amarin Could Still Turn Profitable [View article]
    Even Dr.Nissen ,Chair of the Cleveland Clinic told me in March,2013 that he would change his mind based on Reduce-It study. He called Jelis study weak study.
    I sent him my Lipid profile data from 2009-2013. I plan to have him as my cardiologist--and to put stent when needed.
    I have bought insurance that covers Cleveland Clinic over Medicare--100%.
    Oct 27 12:05 PM | Likes Like |Link to Comment
  • Amarin Could Still Turn Profitable [View article]
    Matt Herper of Forbes sent me an E mail in which he said,Reduce_It study must be continued as it is a great signal for doctors(not patients).
    Previously he wrote an aticle-citing SCIENCE.
    But now he is saying ,Commercial reasons -as that would keep VASCEPA on growth path for >500mg. group.
    Oct 27 12:00 PM | Likes Like |Link to Comment
  • Amarin Could Still Turn Profitable [View article]
    Agree with you.
    The problem is Joe Z.--remember his statement to Bloomberg in July,2011 when stock was at 19$/share--want to talk if offer is north of 30$/sh.
    Then-- partnerships are Messy-that's what Joe Z. said.
    Look at Pharamcyclics-- it went from 79.81 $/share in 2000 to 0.75$/share in March,2008 and now is 125.67$/sh.
    Richard Miller,CEO wrote an Op Ed in 2007 in Wall Street journal after FDA rejected their dug for brain cancer.He is a great scientist--but brought the co. to knees-as NO one would lend any money to them in 2008. It was Robert Duggan who stepped in 2007 and later took over from Miller in Sept.2008. He lent 6.4 mil.$ and also bought 20% of all shares over next 2 yrs. He takes ZERO salary,COO takes 266,000$/yr. salary.
    The Board of Director should ask top officers to accept $1 per year for 2014-2015. Those who decline-should be allowed to leave-as they have no confidence in Amarin's turnaround. Hey they have made millions in 2011,2012 and 2013.
    Oct 27 11:56 AM | Likes Like |Link to Comment
  • Amarin: Potentially Worth $3 To $4 Without Expanded Approval [View article]
    Hello,
    I have read SA and AF articles.But Forbes--Matt Herper articles have provided useful information over last 14 months.I disagreed with him,but he was right when I spoke with his quoted doctors.
    Here is what he wrote to me 2 days ago.
    Reduce-It is important for SCIENCE(that's what he wrote in his article.)
    Here is what he wrote current valuation is justified if Reduce-It is continued. If Reduce -It is stopped-it will disappoint DOCTORS-not Patients.
    If that happened ,sales could level off at 80 million$ and current market cap is too high for 80 million$ drug sales.
    He is now saying Reduce-It is important for commercial reasons.
    Here is my interpretation of his emailed comments to me.
    Reduce-It study influences many doctors to keep using Vascepa in 2014-2015 to higher levels.
    It shows conviction that Amarin strongly believes in the success of Reduce-It study.
    But what about Amarin's cash viability:
    1) CUT everything sharply to survive-just not sales force.Amarin can not afford CEO and COO--one will do.
    2) Cutback on R&D dramatically-keep the "ESSENTIAL people"
    3) Cutback on SG&A including marketing-- I mean top positions included.Some of these people helped start Vascepa introduction with patients,insurance ,advertising etc.--but now lower level staff with one top marketing person enough. Joe Z.assembled a big talent--for Anchor etc.-Now it is time to cut it sharply.
    John Thero could handle a lot of duties.Amarin does not need a CFO and COO for 80 mil.$ sales in 2014.
    Cut back on Reduce-It by 5-10million$ in 2014-keep it close to 30 mil.$ in 2014 and 15 mil.$ in 2015.
    As far as Sales scenarios exercises--stop it --focus on execution with limited # of people.Who are you trying to impress: Directors or analysts? Analysts have lost confidence in # given by management-that is why stock is close to 2$/share.
    By the way-you don't need an expensive VP for Investor relations-just a junior member should be OK.
    I would cut every one's salary at top (35 people by 50%).Give them stock options instead.How can you justify paying Joe Z. 1 million$ for 80 mil.$ sales co? He should work for 250K$.
    FYI--top 4 at Google take 1$/year salary-they get compensated with stock options.
    If Joe Z.does not like 250K$--consolidate his job with JohnThero.
    Stop going to Investment bankers conferences for 2014-2015.Let John Thero focus on day to day operations.
    I am speaking with watching a co.come back from near bankruptcy in 2003.
    Oct 25 02:44 PM | 6 Likes Like |Link to Comment
  • Amarin Could Still Turn Profitable [View article]
    Matt Herper of Forbes says" Without Reduce-It",Amarin's worth declines.
    He is a respected journalist.I have followed him since last year.
    I tend to agree that "Reduce-It" continuation till the end of 2015 is very important--We should have sufficient data for everyone to know effectiveness of Vascepa.
    Discontinuing will send a negative message to doctors and the future sales of Vascepa for Marine group,TG >500mg
    Oct 24 12:49 PM | Likes Like |Link to Comment
  • Should A Generic Lovaza Worry Amarin Longs? [View article]
    Confused about Gag order for talking about Inflammation.2011 reanalysis of Jelis data confirmed the benefits from lower inflammation-going down dramatically-in a published article.
    Why can't Amarin talk about Inflammation benefits?Dr.Ballantyne has published couple of articles already.
    Reduce-It study participants on Vascepa should see the benefits.I wish/hope some results in 2014.
    Sep 15 01:08 PM | Likes Like |Link to Comment
COMMENTS STATS
198 Comments
137 Likes